PHALLA POV-BRANTLE: Open Payments
NPI 1306250709 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,276 in 83 payments from 11 companies in 2025. Trend: 2023 $1,389 · 2024 $1,072 · 2025 $2,276
Food & beverage: $2,242Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $499 |
| GlaxoSmithKline, LLC. | 32 | $426 |
| Incyte Corporation | 10 | $379 |
| BioCryst US Sales Co., LLC | 6 | $290 |
| CSL Behring | 12 | $289 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $82 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
| Amgen Inc. | 2 | $60 |
| Optinose US, Inc. | 2 | $42 |
Products named: TEZSPIRE, OPZELURA, TRELEGY ELLIPTA, ORLADEYO, Andembry, NUCALA, BREZTRI, DUPIXENT.
Industry payments across CA — which companies pay providers there.
